A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals' combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine dTpa (Boostrix) when administered in healthy adult subjects, after previous booster vaccination with dTpa in study 263855/029 (dTpa-029).

Trial Profile

A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals' combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine dTpa (Boostrix) when administered in healthy adult subjects, after previous booster vaccination with dTpa in study 263855/029 (dTpa-029).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline Biologicals
  • Most Recent Events

    • 16 Aug 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 30 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top